HALOZYME THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.64 USD | +2.20% |
|
+0.08% | +4.55% |
Financials (USD)
| Sales 2024 * | 955M | Sales 2025 * | 1.09B | Capitalization | 4.91B |
|---|---|---|---|---|---|
| Net income 2024 * | 368M | Net income 2025 * | 484M | EV / Sales 2024 * | 6.4 x |
| Net Debt 2024 * | 1.2B | Net Debt 2025 * | 422M | EV / Sales 2025 * | 4.91 x |
| P/E ratio 2024 * |
12.6
x | P/E ratio 2025 * |
9.15
x | Employees | 373 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Halozyme Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.20% | ||
| 1 week | +0.08% | ||
| Current month | -5.01% | ||
| 1 month | -5.32% | ||
| 3 months | +13.15% | ||
| 6 months | +7.93% | ||
| Current year | +4.55% |
1 week
37.73
39.27
1 month
37.7342.30
Current year
33.1542.64
1 year
29.8545.00
3 years
29.8559.46
5 years
12.7159.46
10 years
6.8859.46
| Managers | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 61 | 14-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 41 | 14-12-31 |
Mark Snyder
CMP | Compliance Officer | 57 | 22-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
BRD | Director/Board Member | 70 | 06-07-30 |
| Chairman | 59 | 15-08-04 | |
Barbara Duncan
BRD | Director/Board Member | 59 | 23-02-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.48% | 5 M€ | -1.80% | - | |
| 0.73% | 0 M€ | 0.00% | - | |
| 0.55% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 38.64 | +2.20% | 1,257,647 |
| 24-04-18 | 37.81 | -0.55% | 792,530 |
| 24-04-17 | 38.02 | -0.94% | 733,857 |
| 24-04-16 | 38.38 | -0.88% | 642,294 |
| 24-04-15 | 38.72 | +0.28% | 843,658 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Calendar
2024-04-25
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
37.81
USD
Average target price
50.7
USD
Spread / Average Target
+34.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.55% | 4.8B | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- HALO Stock
